



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2024

SECTION COMMITTEE MEMBERS:

Chairperson: Prof. Dr. Pavel MOHR

Co-chairperson: Prof. Matej Stuhec

Secretary: Dr. Lucie BARTOVA

Councillor:

LIST OF SECTION MEMBERS:

Ayodele ADEBAYO, Preston, United Kingdom
Dickson Olusegun ADEDEJI, Mosjøen, Norway
Joseph ADO-IMOISILI, ANTRIM, United Kingdom
Herta AGAJ, Lezhe, Albania
Süreyya AKYILDIRIM COR, Ankara, Türkiye
Badii AMAMOU, Monastir, Tunisia
A. Elif ANIL YAĞCIOĞLU, Ankara, Türkiye
María Dolores ARIAS, Quito, Ecuador
Taha ARİK
Fatma Gozde AVCI BUYUKDOGAN, Istanbul, Türkiye
Lucie BARTOVA, Vienna, Austria
Valentina BASILE, Orselina, Switzerland
Pierre BAUMANN, Prilly - Lausanne, Switzerland
Anzhela BAZZAEVA, г. Санкт-Петербург, Russian Federation
Hajer BEN MUSTAPHA, Etampes, France
Rolland BENJAMIN, BRON, France
Samrat Singh BHANDARI, Gangtok, India
Haije BIJ DE WEG, Leeuwarden, Netherlands
István BITTER, Budapest, Hungary
Julio BOBES, Oviedo, Spain
Jacques A.j. BOERMANS
Erkan BOLAT, Ankara, Türkiye
Sovady BORA, Anthony, France
Claudio BRASSO, Turin, Italy
Matthew BROOME, Birmingham, United Kingdom
Martin BRUNOVSKY, Klecany, Czech Republic
Elena Daniela BUHAŞ RAMOCEA, Oradea, Romania
Ayça CAN UZ, İstanbul, Türkiye
Marisa CASANOVA DIAS
Sinem ÇETİN DEMİRTAŞ, Adana, Türkiye
Moussa Antoine CHALAH, Paris, France
Pritam CHANDAK, NAGPUR, India
Masa COMIC
Raul Alberto CORTES LADINO, Miami Beach, United States
Jürgen DE FRUYT, Brugge, Belgium



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2024

Arie DE WERK, Netherlands
Mustafa DINÇER, AYDIN, Türkiye
Gizem DOGANCALI-YANCHEV, Pleven, Bulgaria
Luiz DRATCU, London, United Kingdom
Jonas EBERHARD, Lund, Sweden
Defne ERASLAN, Karlsruhe, Germany
Jacobus ERASMUS, West Melbourne, Australia
Damla ERBİL, Ankara, Türkiye
Orkhan FARAJLI, Baku, Azerbaijan
Maria FILIP, Lodz, Poland
Igor FILIPCIC, Zagreb, Croatia
Michele FORNARO, New York, United States
Ehsan FOTOUHI ARDEKANI, Bad Zwischenahn, Germany
Silvana GALDERISI, Naples, Italy
Maria Paz GARCIA-PORTILLA GONZALEZ, Oviedo, Spain
Sundar GNANAVEL, Morpeth, United Kingdom
Marcos GÓMEZ-REVUELTA, Santander, Spain
Heinz GRUNZE, Weinsberg, Germany
Willem Cornelis Pieter GUIJT, Katwijk ZH, Netherlands
Ahmet GüRCAN, Ankara, Türkiye
Josep Maria HARO, Barcelona, Spain
Shahzain HASAN, Karachi, Pakistan
Morten HATLEN, Bergen, Norway
Cyril HÖSCHL, Praha 8, Czech Republic
Sofiya HRECHUKH, Lviv, Ukraine
Robert HUNTER, Glasgow, United Kingdom
Bekzod IBADULLAYEV, Urgench, Uzbekistan
Zhuchenko IHOR, Vinnytsia, Ukraine
Angela IZQUIERDO DE LA PUENTE, Madrid, Spain
Sanjay JAIN, Birmingham, United Kingdom
Eddynell JIMENEZ MANZUETA, MAO VALVERDE, Dominican Republic
Siegfried KASPER, Vienna, Austria
Ozge KILIC, Istanbul, Türkiye
Pınar KızıLAY ÇANKAYA, Ankara, Türkiye
Nikolaos KOKRAS, Athens, Greece
Halldor KOLBEINSSON, Reykjavik, Iceland
Volodymyr KOROSTIY, Kharkiv, Ukraine
Theodoros KOUTSOMITROS, Thessaloniki, Greece
Ivan KOYCHEV, OXFORD, United Kingdom
Fabian KRAXNER, Hedingen, Switzerland
Anna KRUPA, Cracow, Poland
Desiree LACIDA, Davao City, Philippines
Aiste LENGVENYTE, Montpellier, France
Jona LEWIN, London, United Kingdom
Jan LIBIGER, Hradec Kralove, Czech Republic



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2024

Tino LINDNER, Utrecht, Netherlands
Antonella LITTA, Bari, Italy
Maxime LOGNOUL, Welkenraedt, Belgium
Livia Andreea LUPSA, Göteborg, Sweden
Marilena-petruta MAIDAN
Aram MAMIKONYAN, Yerevan, Armenia
Kamel MARZOUKI, LONDON, United Kingdom
Kotchuthressia MATHEW, Manjeri, India
Declan MCLOUGHLIN, Dublin, Ireland
Haque MD. RASHIDUL, Dhaka, Bangladesh
Antonio METASTASIO, London, United Kingdom
Milos MILUTINOVIC, Skopje, Macedonia
Dimitrie-filip MOGÎRZAN
Pavel MOHR, Klecany, Czech Republic
Hans-jürgen MÖLLER, München, Germany
Boglarka ORBAN-SZIGETI
Laura ORSOLINI, Ancona, Italy
Galyna OSADCHA, Kyiv, Ukraine
Raul Felipe PALMA ALVAREZ, Barcelona, Spain
Igor PANTIĆ, Belgrade, Serbia
Kollarova PATRICIE
Irene PINUCCI, Rome, Italy
Chrysostomi Maria PLATSA, Greater London, United Kingdom
Lucian - Ioan POP, Romania
Goran RACETOVIC, Prijedor, Bosnia and Herzegovina
Zoheb RAJ, Ajman, United Arab Emirates
Melanie RIEDER, Strasbourg, France
Sara RODRIGUES, Porto, Portugal
Joshua RODRIGUEZ
Janusz K. RYBAKOWSKI, Poznan, Poland
Farzaneh SAEEDZADEH SARDAHAEE, Trondheim, Norway
Şengül ŞAHİN, Gaziantep, Türkiye
Hamza SALEMI, Kabul, Afghanistan
Virginio SALVI, Ancona, Italy
Andriy V. SAMOKHVALOV, Guelph, Canada
Peter SANTOS, Cagayan de Oro, Philippines
Samuel SARRAZIN, Chevilly Larue, France
Aleksandar SAVIC, Zagreb, Croatia
Gianluca SERAFINI, Genoa, Italy
Angelo Vincenzo SERIO, Massafra, Italy
Sarfaraz Aslam SHORA, Bradford, United Kingdom
Francis SILVEIRA, Governador Valadares MG, Brazil
Sumeet SINGH, Pathankot, India
Marcin SIWEK, Kraków, Poland
Anthony SOARES, Greater Manchester, United Kingdom



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2024

Amro SOLIMAN, Cairo, Egypt
Aldo STOPPA, BARCELONA, Spain
Matej Stuhec, Ormoz, Slovenia
Züleyha SUSAM, Düsseldorf, Germany
Richard SYKES, Pretoria, South Africa
Attila SZABO, Oslo, Norway
Petra Andrea SZILAGYI, Budapest, Hungary
Hina TAHSEEN, Knutsford, United Kingdom
Cristiana TAPOI, Bucharest, Romania
Florence THIBAUT, PARIS, France
Shruti TIWARI, New York, United States
Agata TODZIA-KORNAŚ, Warszawa, Poland
Ngoc TRAN
Ramachandra V., Edgware, United Kingdom
Doina VACALIE, Frederikssund, Denmark
Octavian VASILIU, Bucharest, Romania
María Isabel VÁSQUEZ-SUYO, Lima, Peru
Timothy VEAL, La Jolla, United States
Petar VIDOVIĆ
Andreja VUCHKOV, Toorak, Australia
Rebecca WARD
Angelika WIECK, Manchester, United Kingdom
Damla YILDIRIM
İmran Gökçen YILMAZ KARAMAN, Eskişehir, Türkiye
Virginia YOUSSEF
Nikola ŽAJA, Zagreb
Besmira ZENELAJ, Tirana, Albania

LAST SECTION COMMITTEE ELECTIONS HELD:

Date: 08 April 2024
Venue: EPA Congress Budapest, Hungary

ACTIVITIES OF THE SECTION IN 2024:

Meetings/events

Section Business Meeting

Description:

The section held one in-person meeting during the EPA Congress in Budapest, Hungary, on 8th April 2024.

The section had an in-person election during the section meeting at the EPA Congress in Budapest, Hungary, on 8th April 2024.



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2024

Results:

- Chairperson: Prof. Pavel MOHR
- Co-chairperson: Assoc. Prof. Matej ŠTUHEC
- Secretary: Priv.-Doz. DDr. Lucie BARTOVA
- Past-Chairperson: Prof. István BITTER

Location: 32th EPA Congress (April 6th-9th, 2024), in Budapest

Start date: 08/04/2024

End date: 08/04/2024

Treatment guidelines and clinical practice in the management of depression (focus on comorbidity)

Description:

- Chairs: Pavel Mohr (Czechia), Matej Štuhec (Slovenia)
- Speakers: Judit Balasz, Antoni Ramos-Quiroga, Lucie Bartova, Allan Young
- Description: This symposium addressed challenges in managing depression, focusing on psychiatric and physical comorbidities, their impacts on treatment efficacy, and practical strategies to overcome these challenges.

Location: EPA Congress: The 32nd European Congress of Psychiatry, 6-9 April 2024, Budapest, Hungary.

Start date: 09/04/2024

End date: 09/04/2024

A practice-oriented intensive course on pharmacological treatment of schizophrenia and other



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2024

psychotic disorders

Description:

- Chairs: István Bitter (Hungary), Matej Štuhec (Slovenia)
- Description: This interactive course covered evidence-based treatments, including therapeutic drug monitoring, dosing strategies, management of treatment resistance, and pharmacotherapy in elderly populations.

Location: EPA Congress: The 32nd European Congress of Psychiatry, 6-9 April 2024, Budapest, Hungary.

Start date: 06/04/2024

End date: 06/04/2024

Medication-related issues in antipsychotic treatment during transition from adulthood to elderly age (indications, dosing, interactions)

Description:

- Chairs: Cecile Hanon (France), István Bitter (Hungary)
- Speakers: István Bitter, Gabriela Stoppe, Pavel Mohr, Matej Štuhec, Filip Bouckaert, George Stercu
- Description: This workshop explored the challenges of antipsychotic treatment in older adults, addressing real-world cases, dosing adjustments, and management of drug-drug interactions.

Location: EPA Congress: The 32nd European Congress of Psychiatry, 6-9 April 2024, Budapest, Hungary.

Start date: 07/04/2024

End date: 07/04/2024

Publications

Physical Health of Patients with Schizophrenia: Management of Antipsychotic-Induced Side Effects and Treatment of Comorbid Somatic Conditions

Journal:

In: Fiorillo A., Falkai P., Gorwood P. (Eds.) Mental Health Research and Practice: From Evidence to Experience. Cambridge University Press, 2024. ISBN: 978-1009065979.



EUROPEAN PSYCHIATRIC ASSOCIATION



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2024

Authors:

Mohr P., Štuhec M., Bitter I.

(Expected) Publication date: 08/02/2024

Acknowledged as official Section publication? No

Other Section activities

Description:

EPA Online Talks with Experts Meeting

Event Start date: 03/06/2024 **Event**

End date: 03/06/2024 **Outcomes**

Collaboration with the EPA Section “Early Career Psychiatrists (ECP)” to support ECPs in Europe through a dedicated session in June 2024.

Description:

Collaboration with EMA

- Contribution by Pavel Mohr to the EPA’s statement supporting recommendation for the approval of lecanemab.

- Participation of Pavel Mohr on in the the EMA Workshop on Artificial Intelligence in Amsterdam on November 5, 2025

Event Start date: 05/11/2024 **Event**

End date: 05/11/2024 **Outcomes**

- Contribution by Pavel Mohr to the EPA’s statement supporting recommendation for the approval of lecanemab.



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2024

- Participation of Pavel Mohr on in the the EMA Workshop on Artificial Intelligence in Amsterdam on November 5, 2025

FUTURE ACTIVITIES:

Meetings/events

Psychopharmacology for depression and anxiety in the medically ill patient Description:

The symposium will address the management of anxiety and depressive symptoms in patients with primary somatic diseases, focusing on pharmacodynamics and pharmacokinetic issues of antidepressants, interactions with non-psychotropic medications, and integration with psychotherapeutic strategies. Presentations include clinical vignettes and case-based treatment recommendations.

Chairs: Diogo Telles Correia (Portugal), Pavel Mohr (Czech Republic) Speakers:

15:00 - 15:17: Typical clinical manifestations of anxiety and depression in patients with medical illness and general notions about their treatment. Speaker: Lucie Bartova (Austria)

15:17 - 15:34: Psychopharmacological treatment of anxiety and depression in patients with diabetes. Pharmacodynamics and pharmacokinetic considerations, drug interactions. Speaker: Filipa Novais (Portugal)

15:34 - 15:51: Psychopharmacological treatment of anxiety and depression in patients with liver and/or kidney disease. Pharmacodynamics and pharmacokinetic considerations, drug interactions. Speaker: Matej Stuhec (Slovenia)

15:51 - 16:08: Psychopharmacological treatment of anxiety and depression in patients with cardiological disease. Pharmacodynamics and pharmacokinetic considerations, drug interactions. Speaker: Giorgio Mattei (Italy)

16:08 - 16:30: Q&A



EUROPEAN PSYCHIATRIC ASSOCIATION



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2024

Partners:

This session is jointly organized by the Sections on Consultation Liaison Psychiatry and Psychosomatics & Psychopharmacology

Location: EPA Congress. The 33rd European Congress of Psychiatry, 05-08 April 2025, Madrid (Spain)

Start date: 08/04/2025

End date: 08/04/2025

Therapeutic drug monitoring issues in clinical practice: from adulthood to elderly age Description:

Therapeutic drug monitoring (TDM) involves measuring drug concentrations in plasma and is a valuable method for individualizing doses in patients. This workshop will focus on the practical aspects of TDM use in clinical practice, particularly dose adjustments and recognizing drug-drug interactions. The structure includes a case presentation and audience interaction via tools like Mentimeter.

Chairs: Lucie Bartova (Austria), Cecile Hanon (France) Speakers:

10:00 - 10:14: Therapeutic drug monitoring for mood stabilizers in elderly: a case report. Speaker: Georgios Schoretsanitis (Switzerland)

10:14 - 10:28: Pharmacokinetic background of therapeutic drug monitoring in this case. Speaker: Matej Stuhec (Slovenia)

10:28 - 10:42: Therapeutic drug monitoring in clozapine treatment. Speaker: Pavel Mohr (Czech Republic) 10:42 -

10:56: How to use therapeutic drug monitoring for comorbidities management in this case. Speaker: Jens Benninghoff (Germany)

10:56 - 11:10: Therapeutic drug monitoring and psychiatric curriculum based on the clinical cases. Speaker: István Bitter (Hungary)

11:10 - 11:30: Q&A

Partners:

This session is jointly organized by the Sections on Psychopharmacology & Old Age Psychiatry.



EUROPEAN PSYCHIATRIC ASSOCIATION



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2024

Location: EPA Congress. The 33rd European Congress of Psychiatry, 05-08 April 2025, Madrid (Spain)

Start date: 06/04/2025

End date: 06/04/2025

Are side effects needed for efficacy in psychiatric treatments? Description:

This session is organized by the Section on Psychopharmacology. Since the introduction of the first psychotropic drugs into clinical practice, psychiatrists have struggled to find the optimum balance between wanted and unwanted effects. This symposium critically examines the relationship between therapeutic and adverse effects of psychotropics in treating various mental disorders, including depression, schizophrenia, and substance use disorders.

Chairs: Lucie Bartova (Austria), Pavel Mohr (Czech Republic) Speakers:

08:00 - 08:17: Cardiovascular and metabolic side effects of antipsychotic treatment in schizophrenia: What comes first? Speaker: Peter Falkai (Germany)

08:17 - 08:34: Are side effects necessary for antidepressant treatment? Speaker: Siegfried Kasper (Austria)

08:34 - 08:51: What about the trip? The relationship between ketamine's acute and antidepressant effect. Speaker: Veronika Andrashko (Czech Republic)

08:51 - 09:08: Who wants side effects on Substance Use Disorder's treatment? Speaker: Jose Antoni Ramos-Quiroga (Spain)

09:08 - 09:30: Q&A

Location: EPA Congress. The 33rd European Congress of Psychiatry, 05-08 April 2025, Madrid (Spain)

Start date: 06/04/2025

End date: 06/04/2025

Section Webinar: Evidence-Based Diagnosis and Treatment of Treatment-Resistant Depression – Update and Preview

Description:



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2024

Webinar Overview: Major depressive disorder (MDD) is a common psychiatric condition with a significant subset of patients experiencing treatment-resistant depression (TRD). The webinar will address diagnostic challenges, including the exclusion of pseudo-resistance, and provide an overview of evidence-based pharmacological and non-pharmacological treatments, including innovative approaches.

- Moderators: Lucie Bartova, Siegfried Kasper
- Speakers: Georg Kranz, Pia Baldinger-Melich, Christoph Kraus
- Duration: 90 minutes, including a Q&A session.
- Target Audience: Clinical Psychiatrists and Neuroscientists at all career stages.

Location: Online

Start date: 27/10/2025

End date: 27/10/2025

Development of Educational Resources Description:

- Participation in the creation of the European Training Requirements for Psychopharmacology and an updated curriculum program for 2025, contributing to the development of the European Board Examination in Psychiatry.

Location: diverse

Start date: 01/01/2025

End date: 31/12/2025

Other Section activities

Description:

EPA Online Talks With Experts

Event Start date: 01/01/2025

Event End date: 31/12/2025

Continued collaboration with the EPA Early Career Psychiatrists Section for online expert talks.



EUROPEAN PSYCHIATRIC ASSOCIATION



EPA PSYCHOPHARMACOLOGY SECTION REPORT 2024

FUNDING IN 2024

Income: None Source(s)
of funding:

None

Expenditure: None

Balance: None

EPA Treasurer audit: No

Confirmation that income / expenditure is via EPA: No